WO1994002138A1 - Pharmaceutical composition and method of treatment for serotonin depletion illness - Google Patents
Pharmaceutical composition and method of treatment for serotonin depletion illness Download PDFInfo
- Publication number
- WO1994002138A1 WO1994002138A1 PCT/US1993/006554 US9306554W WO9402138A1 WO 1994002138 A1 WO1994002138 A1 WO 1994002138A1 US 9306554 W US9306554 W US 9306554W WO 9402138 A1 WO9402138 A1 WO 9402138A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- sdi
- sulpiride
- amitriptyline
- year old
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Definitions
- THIS invention relates to the treatment of patients presenting with synaptic fatigue related conditions and to pharmaceutical compositions for use in such treat- ent. More particularly this invention relates to the treatment of a condition which the inventor has characterised as serotonin depletion illness [herein ⁇ after referred to as SDI] .
- SDI is a central neurochemical disorder involving the all important mid- line raphe nucleus in the medulla, the RAS, hypothalmus and the entire autonomic nervous system.
- SDI is a physical condition found mainly in urban societies where an abundance of sensory input [popular ⁇ ised as stress] exhausts the midline raphe nucleus in its production of serotonin [5-Hydroxytryptamine] and in this way causes sleep disturbances, hyperalgesia [defective pain modulation] and alteration of mood [depression and irritability].
- the inventor is of the view that conditions such as myofascial syndrome, fibromyalgia, fibrositis, masked depression, yuppie flu [epidemic myalgic encephalomyel- itis syndrome] and a host of chronic pain conditions as well as indications of altered immunity may be placed under one umbrella, namely that of SDI. cordingly it is suggested that SDI should be included in the differential diagnosis of a multiplicity of conditions which include:
- SDI is an easily recognisable clinical diagnosis and not a single laboratory or other special examination is necessary before institution of treatment.
- This invention provides for the use of a serotonin agonist in combination with sulpiride in the production of an intravenous infusion composition for use in the
- the serotonin agonist is preferably selected from the group consisting of the tricyclic anti-depressants, maprotiline hydrochloride and mianserin hydrochloride.
- the serotonin agonist is preferably amitriptyline.
- an intravenous infusion composition comprising amitriptyline in combination with sulpiride in a physiologically acceptable carrier.
- the carrier may be a normal saline solution.
- an intravenous infusion product in unit dosage form for use in the treatment of a stress related condition, including SDI comprising a container and an hypodermic needle secured thereto, the container containing a composition comprising between 10 and 50 mg amitriptyline and between 50 and 200 mg sulpiride in a normal saline carrier.
- the container may be in the form of an infusion bag.
- this aspect of the invention there is provided a three day treatment course of the infusion product of the invention com ⁇ prising three infusion products in unit dosage form as described above, the three containers each containing about 50 millilitres of normal saline, about 100 mg sulpiride and respectively about 10 mg to 40 mg amitriptyline.
- SUBSTITUTE SHEET amitriptyline dosage to a number of patients presenting with the typical synaptic fatigue symptoms described above.
- This treatment regimen usually resulted in excellent pain modulation, mood elevation and restor- ation of delta sleep after which the patients were kept on low dosage amitriptyline or another serotonin agonist [per os] for at least six months.
- the invention also relates to a method of treating SDI by the simultaneous or sequential intravenous infusion of a serotonin agonist and sulpiride as described above.
- SUBSTITUTE SHEET academic was suffering from chronic fatigue to such an extent that she was virtually bedridden for seven years and was diagnosed with myalgic encephalomyelitis. She had been extensively investigated and treated by her specialist physician for the previous seven years, using mainly vitamins and magnesium supplementation. She had been prescribed bed rest and the exclusion of various foodstuffs. One day after treatment according to the invention she felt so much better that she went for a run of several kilometers.
- a fifty-five year old bank manager with cluster headaches and accompanied Horner Syndrome was cured by the treatment according to the invention after many years of multiple examinations, hospital admissions and consultations.
- a forty-two year old housewife and a forty-four year old part-time worker presented with the same blood pictures after treatment failure, which was corrected after attending to their hormone picture.
- a thirty-five year old male divorce victim showed severe anger and rages. He sought psychological counseling because he felt self-destructive. He felt rested and self-contented after the first infusion of the composition according to the invention and recovered fully after the standard treatment.
- amitriptyline a serotonin agonist [it promotes the recycling of this important modulator] together with Sulpiride, which stimulates the secretion
- SUBSTITUTE SHEET of the endogenous opoids have a potent synergistic action.
- it is given intravenously to obtain bolus infusion over the blood brain barrier into the aquaductus of Sylvius so that the medicated cerebral spinal fluid will attend to the dry synaptic vesicles of not only the synaptic knobs in the medulla but also of the synaptic knobs of the dendrites and axons in other parts of the central nervous system.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93917128A EP0651638A1 (en) | 1992-07-15 | 1993-07-15 | Pharmaceutical composition and method of treatment for serotonin depletion illness |
AU46746/93A AU4674693A (en) | 1992-07-15 | 1993-07-15 | Pharmaceutical composition and method of treatment for serotonin depletion illness |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA92/5265 | 1992-07-15 | ||
ZA925265 | 1992-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994002138A1 true WO1994002138A1 (en) | 1994-02-03 |
Family
ID=25581876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/006554 WO1994002138A1 (en) | 1992-07-15 | 1993-07-15 | Pharmaceutical composition and method of treatment for serotonin depletion illness |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0651638A1 (en) |
AU (1) | AU4674693A (en) |
WO (1) | WO1994002138A1 (en) |
ZA (1) | ZA935078B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998043646A1 (en) * | 1997-03-27 | 1998-10-08 | Akzo Nobel N.V. | New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders |
US6056715A (en) * | 1995-12-12 | 2000-05-02 | Omeros Medical Systems, Inc. | Surgical irrigation solution and method for inhibition of pain and inflammation |
US6150353A (en) * | 1997-03-27 | 2000-11-21 | Akzo Nobel N.V. | Therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders |
US6413961B1 (en) | 1995-12-12 | 2002-07-02 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain and inflammation |
US6596759B2 (en) | 1997-08-19 | 2003-07-22 | Mitsubishi Chemical Corporation | Medicament for treatment of irritable bowel syndrome |
-
1993
- 1993-07-14 ZA ZA935078A patent/ZA935078B/en unknown
- 1993-07-15 WO PCT/US1993/006554 patent/WO1994002138A1/en not_active Application Discontinuation
- 1993-07-15 AU AU46746/93A patent/AU4674693A/en not_active Abandoned
- 1993-07-15 EP EP93917128A patent/EP0651638A1/en not_active Withdrawn
Non-Patent Citations (4)
Title |
---|
BUDAVARI et al. (Editors), "The Merck Index (11th Ed.)", published 1989 by Merck & Co. (NJ), see pages 80, 901-902, 971 and 1421. * |
Eur. J. of Pharmacol., Vol. 5, No. 4, issued 1969, CARLSSON et al., "Effect of Antidepressant Drugs...-m-Tyramine", pages 357-366, see CA 71(5): 20767z. * |
GILMAN et al. (Editors), "The Pharmaceutical Basis of Therapeutics (6th Ed.)", Published 1980 by MacMillan (NY), see pages 418-424. * |
Societe D'Etudes Scientifiques et Industrielles, issued 12 May 1969, "Antidepressant Compositions Consisting of Sulpride and Amitriptyline", see CA 74(24): 130361g. * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6056715A (en) * | 1995-12-12 | 2000-05-02 | Omeros Medical Systems, Inc. | Surgical irrigation solution and method for inhibition of pain and inflammation |
US6242447B1 (en) | 1995-12-12 | 2001-06-05 | Omeros Medical Systems, Inc. | Surgical irrigation solution and method for inhibition of pain and inflammation |
US6261279B1 (en) | 1995-12-12 | 2001-07-17 | Omeros Medical Systems, Inc. | Surgical irrigation solution and method for inhibition of pain and inflammation |
US6413961B1 (en) | 1995-12-12 | 2002-07-02 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain and inflammation |
WO1998043646A1 (en) * | 1997-03-27 | 1998-10-08 | Akzo Nobel N.V. | New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders |
US6150353A (en) * | 1997-03-27 | 2000-11-21 | Akzo Nobel N.V. | Therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders |
CZ298105B6 (en) * | 1997-03-27 | 2007-06-27 | N.V. Organon | Therapeutic combination of mirtazapine and an antipsychotic agent, and pharmaceutical composition |
US6596759B2 (en) | 1997-08-19 | 2003-07-22 | Mitsubishi Chemical Corporation | Medicament for treatment of irritable bowel syndrome |
Also Published As
Publication number | Publication date |
---|---|
EP0651638A1 (en) | 1995-05-10 |
AU4674693A (en) | 1994-02-14 |
ZA935078B (en) | 1994-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Walker et al. | Pseudotumor cerebri associated with prolonged corticosteroid therapy: reports of four cases | |
Stockings | A new euphoriant for depressive mental states | |
WO1994002138A1 (en) | Pharmaceutical composition and method of treatment for serotonin depletion illness | |
Waisbren | Pyogenic Osteomyelitis and Arthritis of the Spine Treated with Combinations of Antibiotics and Gamma Globulin: A Preliminary Report | |
Sommer et al. | Creative-dynamic image synthesis: a useful addition to the treatment options for impotence | |
Magoha | Sildenafil (Viagra) in the treatment of male erectile dysfunction in Nairobi | |
RU2350341C1 (en) | Method of irritable bowel on health resort | |
Gupta et al. | Phenelzine-induced sexual dysfunction treated with sildenafil | |
WIEDER | Addiction to meperidine hydrochloride (demerol hydrochloride): report of three cases | |
Sorter et al. | Constipation in the Aged, Attempts at Therapy | |
RU2281101C2 (en) | Method for treatment of patients with chronic prostatitis | |
US5320601A (en) | Method for treatment of cholelithiasis and chronic hepato- and cholecystopathies secondary to said disease | |
RU2333020C1 (en) | Method of after treatment of patients with postcholecystectomy syndrome | |
Wright | Use of tranquilizers in dermatology | |
RU2016568C1 (en) | Method for treating disseminated sclerosis | |
Russell | Overcoming erectile dysfunction | |
Zhu et al. | Acupuncture treatment in chronic prostatitis | |
SU1122318A1 (en) | Method of treatment of irritable intenstine syndrome | |
EP4403181A1 (en) | A medicinal product for use in administering in the treatment, control and/or prevention of pain | |
Heterophoria | quent sneezing in the morning, due probably to the | |
De Backer | Multicentre study of the efficacy and tolerance of acebutolol versus atenolol in the long term treatment of mild arterial hypertension | |
Reinish et al. | Neuroleptic Malignant Syndrome | |
Beattie | Syncope: a review of the literature | |
CONFIRM | WIDE MARGIN | |
Ford et al. | justment of dosage of penicillin was accomplished after the |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1995 367195 Date of ref document: 19950113 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993917128 Country of ref document: EP |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i | ||
WWP | Wipo information: published in national office |
Ref document number: 1993917128 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993917128 Country of ref document: EP |